Recent News

• 03.30.2026 - Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
• 03.04.2026 - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
• 03.03.2026 - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
• 02.25.2026 - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
• 02.23.2026 - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
• 01.28.2026 - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
• 01.21.2026 - Ensysce Biosciences Expands Global Opioid Patent Portfolio
• 01.08.2026 - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
• 01.05.2026 - Ensysce Biosciences Issues Annual Shareholder Letter
• 12.09.2025 - Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Recent Filings

• 03.30.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.30.2026 - 8-K Current report
• 03.30.2026 - 8-K Current report
• 03.30.2026 - EX-99.1 EX-99.1
• 03.23.2026 - 8-K Current report
• 02.27.2026 - 8-K Current report
• 01.08.2026 - 8-K Current report
• 12.16.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 12.11.2025 - EFFECT Notice of Effectiveness